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Background. Antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been shown to neutralize the 
virus in vitro and prevent disease in animal challenge models on reexposure. However, the current understanding of SARS-CoV-2 
humoral dynamics and longevity is conflicting.
Methods. The COVID-19 Staff Testing of Antibody Responses Study (Co-Stars) prospectively enrolled 3679 healthcare workers 
to comprehensively characterize the kinetics of SARS-CoV-2 spike protein (S), receptor-binding domain, and nucleoprotein (N) 
antibodies in parallel. Participants screening seropositive had serial monthly serological testing for a maximum of 7 months with 
the Meso Scale Discovery Assay. Survival analysis determined the proportion of seroreversion, while 2 hierarchical gamma models 
predicted the upper and lower bounds of long-term antibody trajectory.
Results. A total of 1163 monthly samples were provided from 349 seropositive participants. At 200 days after symptoms, >95% 
of participants had detectable S antibodies, compared with 75% with detectable N antibodies. S antibody was predicted to remain 
detectable in 95% of participants until 465 days (95% confidence interval, 370–575 days) using a “continuous-decay” model and in-
definitely using a “decay-to-plateau” model to account for antibody secretion by long-lived plasma cells. S-antibody titers were cor-
related strongly with surrogate neutralization in vitro (R2 = 0.72). N antibodies, however, decayed rapidly with a half-life of 60 days 
(95% confidence interval, 52–68 days).
Conclusions. The Co-Stars data presented here provide evidence for long-term persistence of neutralizing S antibodies. This has 
important implications for the duration of functional immunity after SARS-CoV-2 infection. In contrast, the rapid decay of N anti-
bodies must be considered in future seroprevalence studies and public health decision-making. This is the first study to establish a 
mathematical framework capable of predicting long-term humoral dynamics after SARS-CoV-2 infection.
Clinical Trials Registration. NCT04380896.
Keywords.  immunity; serology; antibody; ELISA; kinetics; neutralization; SARS-CoV-2; COVID-19; virus; nucleoprotein; 
spike protein.
Since appearing as a cluster of pneumonia cases in Wuhan, 
China, coronavirus disease 2019 (COVID-19), caused by se-
vere acute respiratory syndrome (SARS) coronavirus (CoV) 
2 (SARS-CoV-2), has rapidly spread worldwide [1]. As of 24 
April 2021, a total of 145 774 566 cases have been recorded cases 
globally, resulting in >3 million deaths [2]. Specific immuno-
globulin (immunoglobulin [Ig] G) antibody responses to the 
SARS-CoV-2 trimeric spike (S) protein, nucleoprotein (N), and 
the receptor-binding domain (RBD) develop 6–15 days after di-
sease onset [3]. The S protein, which contains the RBD, binds 
to host cells via the angiotensin-converting enzyme 2 (ACE-2) 
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5]. Nucleoprotein plays an important role in transcription en-
hancement and viral assembly [6].
Neutralizing SARS-CoV-2–specific antibodies to the S and 
RBD antigens, have been shown to be correlated with viral 
neutralization in vitro as well as to protect against disease in 
animals after passive transfer of convalescent or monoclonal 
antibodies [7–11]. It is unclear, however, whether reinfection 
can occur in humans who mount a humoral response after 
primary SARS-CoV-2 infection and achieve viral clearance. 
Neutralizing SARS-CoV antibodies have been shown to com-
monly persist up to 2–3  years after infection, particularly in 
hospitalized patients [12, 13], with reports demonstrating sero-
positivity as long as 12–17 years after infection [14, 15]. Existing 
longitudinal studies of SARS-CoV-2 are limited by inadequate 
modeling of antibody dynamics, short duration, low sampling 
density, and insufficient frequency of follow-up [16–26]. Fitting 
locally estimated scatterplot smoothing or equivalent lines of 
best fit to the data also fails to provide a mathematical frame-
work for evaluating long-term antibody responses [16–18, 27].
To evaluate antibody kinetics and longevity after SARS-
CoV-2 infection, we undertook the prospective COVID-19 
Staff Testing of Antibody Responses Study (Co-Stars). Detailed 
demographic, clinical and socioeconomic data were collected 
and mathematical models developed to characterize longitu-
dinal humoral kinetics from initial antibody boosting to subse-
quent decay. To predict long-term antibody dynamics, we fitted 
2 models based on the gamma distribution: one that assumed 
persistent antibody decay [28] and an alternate that allowed for 
an eventual plateau, to account for sustained antibody produc-
tion by long-lived plasma cells [29, 30].
MATERIALS AND METHODS
Study Setting and Design
Co-Stars was a 1-year single-center, 2-arm, prospective cohort 
study of healthcare workers at Great Ormond Street Hospital for 
Children, London. The study was approved to start by the UK 
National Health Service Health Research Authority on 29 April 
2020 and registered on ClinicalTrials.gov (NCT04380896). 
Written informed consent was obtained from all participants 
before recruitment. The Study Protocol and Supplementary 
Methods and Materials submitted with this article include 
detailed methods, power calculations. and the data analysis 
approach.
Study Participants
All hospital staff members ≥18 years of age were eligible for the 
study, provided they did not display symptoms consistent with 
SARS-CoV-2 infection at recruitment. Those who were sig-
nificantly immunosuppressed or who had previously received 
blood products (including immunoglobulins or convalescent 
sera) since September 2019 were excluded from the study.
Data Collection
Participants undertook a detailed, standardized online question-
naire at study entry. This included sociodemographic factors, de-
tails of previous exposure to and symptomatic episodes consistent 
with COVID-19, any subsequent complications, previous SARS-
CoV-2 diagnostic test results, medical and contact history, and a 
comprehensive assessment of risk factors for exposure, suscepti-
bility to infection, and severe disease. Blood samples were also taken 
at baseline and each follow-up visit for SARS-CoV-2 serology.
Polymerase Chain Reaction Measurement of SARS-CoV-2 Serum Antibody 
and Viral RNA 
All 3657 participants underwent a screening enzyme-linked 
immunosorbent assay (ELISA) with the EDI assay. Those who 
were identified as seropositive by the EDI assay and provided 
≥2 samples had serology repeated by the Meso Scale Discovery 
(MSD) Chemiluminescent assay that simultaneously detects 
and quantifies anti–SARS-CoV-2 IgG specific for trimeric S 
protein, RBD, and N.
Follow-up Appointments
All seropositive participants were followed up monthly for re-
peat antibody testing. Seronegative participants were followed 
up every 6 months. At each follow-up visit, participants com-
pleted a shortened version of the baseline questionnaire, fo-
cusing on any recurrent COVID-19 exposure and/or symptoms.
Study Outcomes
The primary outcome of the study was to establish humoral dy-
namics after SARS-CoV-2 infection. Kaplan-Meier survival anal-
ysis was used to compare and plot the time to negativity for each 
antibody. Two mixed effects gamma models were used to predict 
the antibody trajectory over time (Supplementary Methods). The 
“gamma-decay model” hypothesized continuous antibody decay 
and did not account for long-lived plasma cell antibody pro-
duction. In contrast, the “gamma-plateau” model allowed for 2 
phases of plasma cell production: “short-lived” plasma cells, fol-
lowed by a subsequent robust long-lived plasma cell response that 
maintains circulating long-term antibody titers [31].
Surrogate Neutralization Assay
A 96-well custom competition assay, designed to measure the 
inhibition of ACE-2 receptor binding to S protein or RBD by 
serum-derived antibody (MSD), was performed on 94 serial 
samples from 46 participants (2 participants had 3 serial sam-
ples) to establish in vitro correlates of functional immunity.
RESULTS
Participant Demographics
A total of 3679 healthcare workers at Great Ormond Street 
Hospital were enrolled in the study, of whom 733 (19.9%) were 
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these seropositive participants 49% were completely asymp-
tomatic (359 of 733). Of those who were symptomatic, 349 
were confirmed seropositive by the MSD assay and provided 
≥2 monthly samples for the primary outcome analysis of anti-
body dynamics (Table 1). This group was followed up monthly 
for a maximum of 7 months and provided 1163 serial monthly 
serological samples. 
The median follow-up time per participant was 122 days (in-
terquartile range, 65–157  days), with a maximum follow-up 
time of 262 days from symptom onset. The majority of partici-
pants 252 of 349 (72%) donated≥ 3 samples during follow-up, 
with a maximum of 7 samples. Most seropositive participants 
(80%) were women, and these participants had a mean age of 
39  years, representative of the underlying population struc-
ture of the hospital. The predominant symptoms reported were 
cough 225 of 349 (64%) and myalgia 225 of 349 (64%), followed 
by ageusia and anosmia in 210 of 349 (60%) and 201 of 349 
(58%), respectively.
Table 1. Demographic Characteristics of Study Participants and Variables Associated With High Peak Antibody Titers
Characteristic or Variable Participants, No. (%)a 
Coefficient for Association With  
Increased S Antibody Titers (P Value)
All study recruits, no. 3679 …
Seropositive participants with ≥2 samples 349 (100) …
Monthly samples, total no. 1163 …
Age, y   
 18–30 82 (24) Reference
 30–40 109 (31) −0.27 (.2)
 40–50 83 (24) −0.15 (.5)
 50–60 56 (16) 0.09 (.74)
 60–70 19 (5) 0.24 (.5)
Sex   
 Female 259 (80%) −0.3 (.2)
 Male 190 (20)  
Profession   
 Allied health professionals 83 (24) Reference
 Nurse 101 (29) 0.12 (.53)
 Manager 1 (<1) 0.64 (.5)
 Cleaner, caterer, or porter 18 (5) 0.4 (.3)
 Physician 49 (14) −0.18 (.5)
 Scientist 5 (1) 0.23 (.7)
Symptoms   
 Anosmia/ageusia 201 (58)/210 (60) 0.54 (.01)b
 Cough/shortness of breath/wheezing 225 (64)/130 (37)/67 (19) 0.3 (.14)
 Diarrhea/vomiting/diminished appetite 77 (22)/24 (7)/32 (9) 0.3 (.13)
 Extreme fatigue/myalgia 199 (57)/225 (64) −0.08 (.65)
 Fever/rigors 175 (50)/27 (8) 0.37 (.03)b
 Other 174 (50) Reference
Symptom severity   
 Attended hospital 11 (3) …
 Admitted to hospital 1 (0.2) … 
Any comorbid condition   
 Yes 42 (13) 0.05 (.8)
 No 307 (87) Reference
Symptom duration,   
mean (IQR), d
24 (7–27) 0.0007 (.8)
Ethnic background   
 BAME 97 (29) 0.42 (.02)b
 Non-BAME 252 (71) Reference
Body mass index   
 18–25 91 Reference
 25–30 42 0.57 (.03)b
 30–40 34 0.69 (.03)b
 Missing or unknown 182 NA
Abbreviations: BAME, black, Asian, and minority ethnic; IQR, interquartile range; NA, not applicable; S, spike protein.
aData represent no. (%) of participants unless otherwise specified.
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Factors Associated With Increased Peak Antibodies and Rapid Decay
Multivariate analysis demonstrated that fever, rigors, ageusia, 
anosmia, high body mass index, and black, Asian, and mi-
nority ethnic backgrounds were all associated with higher peak 
S-antibody titers (Table 1). No variables were identified as inde-
pendently associated with the rate of antibody decay.
Observed Antibody Kinetics and Seroreversion
Serial monthly serological measurements from 349 participants 
demonstrated a rapid rate of decay of the N antibody relative 
to the S and RBD antibodies (Figure 1). The S-antibody assay 
identified 342 of 349 participants (98%) who were seroposi-
tive to any of the S, RBD, or N antibodies. In comparison the 
RBD and N assays identified 332 (95%) and 333 (95%) who 
were seropositive, respectively. The sensitivity of the RBD- and 
N-antibody assays further declined with time relative to the 
S-antibody assay. At 150  days after infection 249 of the 349 
participants initially seropositive for the N antibody provided 
samples for analysis. Only 233 of 249 remained positive to the 
N antibody (survival probability 95% confidence interval [CI], 
.86–.93) while significantly more, 247 of 249 (.95–.99) remained 
positive to the S antibody. At 200 days after infection, 19 sam-
ples were available for comparison, of which 15 remained pos-
itive to the N antibody (survival probability 95% CI, .56–.80) 
while 19 remained positive to the S antibody (.95–.99, Figure 2).
Modeled Serological Reversion and Proportion of Positive Test Results 
Over Time
Comparison of goodness of fit between models showed that for 
all antigens the decay-to-plateau model provided a better fit to 
the data than the gamma-decay model, although this difference 
was not statistically significant (Supplementary Table 2). Even 
under the most pessimistic assumption of continuous gamma 
decay we estimate that 95% of individuals after infection with 
SARS-CoV-2 will have measurable S antibody until 465  days 
(95% CI, 370–575 days) after symptom onset. Under the gamma-
plateau model, S antibody is predicted to remain detectable in-
definitely (Figure 3A) [15]. The most pessimistic gamma-decay 
model (lower bound) and most optimistic gamma-plateau 
model (upper bound) for each antibody are shown in Figure 
3B. Under both models the N antibody decayed to undetectable 
levels. Even with the gamma-plateau model, 75% of participants 
were predicted to have seroreverted N antibody by 610 (95% CI, 
420–530) days after symptom onset, whereas with the gamma-
decay model 100% of participants had seroreverted N antibody 
by 460 (420–530) days . Fewer serial samples beyond 200 days 
after symptom onset increased the uncertainty in our longer-
term modeled estimates of antibody duration (shaded areas in 
Figure 3).
Antibody Peak, Half-Life, and Plateau
Antibody titers rapidly increased during the first 3 weeks, with 
prolonged high titers reached and maintained between weeks 4 
and 10 after symptom onset. The peak antibody responses for 
the S, RBD, and N antibodies from both raw weekly average 
serial titer and modeled data occurred at 40 (95% CI, 30–63), 
31 (26–38), and 35 (31–42) days, respectively. This finding was 
supported by the both the gamma-decay and gamma-plateau 
models, which provided a similar close fit to this early stage of 
the humoral response (Figure 4A–C).
The modeled half-lives under the gamma-decay and gamma-
plateau models were also very similar, and both models showed 
rapid decay of the N antibody relative to the RBD and S anti-
bodies. The half-lives for the N, RBD, and S antibodies were 60 
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Figure 1. Serial monthly serological measurements from 349 participants up to 262 days after onset of symptoms with severe acute respiratory syndrome coronavirus 2 
infection. Samples from the same participant are linked with thin black lines; dotted red lines represent seroreversion. The gamma-plateau model is superimposed to show 
antibody trajectories; the predicted antibody trajectory (black line) is the median of the posterior distribution of the best model fit and 95% confidence interval, with (light-blue 
shading) and without (dark-blue shading) individual effects. A, Spike protein (S) antibody. B, Receptor-binding domain (RBD) antibody. C, Nucleoprotein (N) antibody, with a 
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(95% CI, 52–68), 102 (92–114), and 126 (112–146) days, respec-
tively, compared with 60 (52–70), 110 (74–148), and 364 (212–
997) days for the gamma-plateau model (Figure 4D and 4E).
Under the gamma-plateau model, the S antibody was pre-
dicted to decay slowly, reaching an eventual stabilized plateau 
at 1825 days since symptom onset (95% CI, 250–3700 days), at 
which point the titer still remained above the threshold for a 
negative test; the N antibody, on the other hand, was predicted 
to decay to a plateau by 610 days, crossing the threshold for a 
negative test.
Surrogate Neutralization Assay
There was a sigmoidal relationship between raw antibody titers 
and percentage binding/ACE-2 receptor blocking for both the 
S and RBD antibodies. Above a threshold S-antibody titer of 
8586 (95% CI, 8160–9095), there was a dramatic increase in 
percentage binding/ACE-2 receptor blocking. Log-transformed 
antibody titers were strongly positively correlated with receptor 
blocking (R2 = 0.72 for S and R2 = 0.77 for RBD antibodies). 
We mapped the point of greatest change in neutralization and 
the lower limit of detection to the final predicted antibody 
titers at the plateau (Figure 5). While the full range of the dis-
tribution of S antibodies was predicted to remain detectable 
indefinitely under the gamma-plateau model, only a small pro-
portion of individuals were predicted to have titers sufficient 
to enable measurable functional binding with our surrogate 
neutralization assay.
DISCUSSION
This prospective cohort study of antibody responses after symp-
tomatic SARS-CoV-2 infection has demonstrated that >95% of 
healthcare workers had persistent detectable S antibodies up 
to 200 days after infection. Our study is the first to provide a 
mathematical modeling framework capable of predicting the 
long-term dynamics of the 3 key SARS-CoV-2 antibodies after 
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Figure 2. Parallel serological measurements of the spike protein (S; blue), receptor-binding domain (RBD; green), and nucleoprotein (N; red) antibodies from the start of 
symptoms. Repeated demonstrate the time to a negative test result from all possible starting positive results. The initial number of seropositive participants providing the 
first sample and the subset still enrolled in the study at any given time point are provided in the table below the graphic. The 95% confidence intervals of this uncertainty are 
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natural infection. Even under our most pessimistic assumptions 
of continuous exponential decay, 95% of individuals were pre-
dicted to remain seropositive to S antibody at 465 days (95% CI, 
370–575 days) while our more optimistic upper bound gamma-
decay model predicted a permanent long-lasting plateau of de-
tectable S antibody.
These data contradict conclusions from studies that have re-
ported rapid waning of antibodies after a few months [22, 24, 
25]. Our findings are consistent with the duration of humoral 
responses observed after SARS-CoV and Middle East respira-
tory syndrome infections; however, modeling of the S-antibody 
trajectory under the MSD assay suggests that in the longer 
term there is a potential to lose neutralizing capability despite 
having detectable IgG [12–15]. Importantly, the long-lasting S 
and RBD antibodies are also well correlated with a surrogate 
SARS-CoV-2 neutralization assay of ACE-2 receptor blocking, 
strongly suggesting that long-term measurable S-antibody 
levels are functionally important.
In contrast to the S antibody, the N antibody was observed to 
serorevert in 56 of 349 participants over the course of the study 
alone and had a modeled half-life of 60 days. This has important 
implications for diagnostic testing, epidemiological modeling, 
and public health decision making, which often rely on the N 
antibody to estimate SARS-CoV-2 seroprevalence. This finding 
may also explain some unexpectedly low estimates of popula-
tion prevalence in high-burden countries [32].
The persistence of detectable S and/or RBD antibody com-
pared with the rapid decay of the N antibody has also been 
observed in convalescent serum samples obtained from SARS 
survivors, 17 years after infection [14]. The mechanisms under-
lying this observation warrant further investigation. Differences 
in the epitope structure [33], immunogenicity, and presentation 
to B cells may affect the production, maturation, and longevity 
of the plasma cells that secrete these antibodies [34–37]. Distinct 
T-helper cell interactions at the germinal center may further de-
termine B-cell and humoral dynamics, as previously observed 
in the context of the response to different HIV proteins [38]. 
The nucleoprotein is more conserved across CoVs than RBD, 
potentially leading to cross-reactive memory responses, with 
differing kinetics and less contribution from naive B cells [39].
To date, no studies have comprehensively modeled the nature 
and duration of antibody responses to different SARS-CoV-2 
epitopes. Long et al [19], Seow et al [22] and Ibarrondo et al [20] 
demonstrated rapid decay of SARS-CoV-2 antibodies within 
the first 3 months after infection, particularly in mildly symp-
tomatic cases. In comparison, others have reported that the 
S and/or RBD antibodies are correlated with neutralizing re-
sponses and decay slowly, persisting during the study period, up 
to 90–150 days after infection [16–18, 40]. These studies, how-
ever, are limited by their shorter sampling time frame, lower 
sampling density, and lack of appropriate modeling to predict 
antibody trajectory. Implementing locally estimated scatterplot 
smoothing lines of best fit to the data [16–18, 22] or comparing 
the variance of average antibody titers at different time intervals 
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Figure 3. Model-based predictions of time to seronegativity from symptom onset. A, Comparison of the 3 tested antibodies against the spike protein (S; blue), receptor-
binding domain (RBD; green), and nucleoprotein (N; red) for the gamma-plateau (top) and the gamma-decay (bottom) models. B, Differences between the gamma-plateau 
(blue) and gamma-decay (red) models for the 3 tested antibodies: S (top right), RBD (bottom), and N (top left). Colored lines represent median estimates of the posterior 
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Our study is strengthened by the density, frequency, and dura-
tion of sampling collection. The parallel evaluation of antibody 
titers to 3 major SARS-CoV-2 proteins by the chemilumines-
cent MSD assay also enabled us to demonstrate the decay of the 
N antibody relative to the S and RBD antibodies. Importantly, 
this is the first study to provide a mathematical framework for 
long-term SARS-CoV-2 antibody responses, modeling both the 
peak and decay after infection and enabling realistic best-case 
and worst-case predictions, as well as considering the impact 
of long-lived plasma cells on future antibody titers. Our work 
provides a detailed, shareable, and reproducible model, with 
parameters that are useful for epidemiological purposes.
None of the seropositive healthcare workers identified in 
this study required hospitalization. Given that the majority of 
COVID-19 cases are managed in the community, our study 
cohort is therefore representative of most SARS-CoV-2 infec-
tions in the general population [41]. Severe disease, however, 
has been associated with higher SARS-CoV-2 antibody titers 
and potentially a longer-lasting humoral response. Studies in 
recent years have also hypothesized that previous exposure to 
seasonal CoVs—to which pediatric healthcare workers may 
be disproportionately exposed—may confer some protection 
against SARS-CoV-2 [11, 14, 42–47] and may therefore need 
to be accounted for when modeling transmission or longevity 
dynamics [48]. However, previously published work from our 
group has demonstrated that those with previous exposure to 
seasonal coronavirus demonstrated little SARS-CoV-2 pseudo-
neutralizing activity, thereby limiting its impact on our findings 
[49].
Furthermore, only 38% of participants in the study had an 
available confirmatory positive polymerase chain reaction 
result. To mitigate this concern, a formal evaluation of the 
MSD assay was undertaken before the beginning of the study, 
using 169 SARS-CoV-2 polymerase chain reaction–positive 
participants; 97.9% sensitivity and 97.4% specificity were 
demonstrated at 21 days after infection [49]. This makes the 
proportion of false-positive serological tests likely to be small 
and therefore to have little impact on our findings. The use of 
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Figure 4. Measured and modeled weekly mean antibody titers. A–C, Real data (green), gamma-plateau model (red), and gamma-decay model (blue) for the spike protein 
(S [A]), receptor-binding domain (RBD [B]), and nucleoprotein (N [C]) antibodies. D, E, Modeled half-lives of antibody decay with the gamma-plateau (D) and gamma-decay (E) 
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a screening ELISA before the chemiluminescent MSD assay 
may also have resulted in some participants being incorrectly 
classified as seronegative, particularly those with low-level 
detectable N-antibodies. A  more sensitive screening test, 
however, would likely lead to an earlier time-to-negativity N 
trajectory, thereby reinforcing our main findings. Limitations 
in sample size >200  days after infection also increased our 
time to negativity and modeling uncertainty. Our estimates of 
the time to negativity are dependent on the negative thresh-
olds and lower limits of detection of the assay. However, our 
model fits, as well as estimates of antibody decay and titers 
(Figure 1), are not dependent on the assay’s lower limits of 
detection.
No definitive quantitative or qualitative correlate of protection 
has been identified yet for SARS-CoV-2 infection, disease, or on-
ward transmission. Nevertheless, live viral neutralization assays 
remain the reference standard in vitro correlate of protection 
against viral infection; as such, lack of formal “authentic” neutral-
ization tests is a study limitation. However, ACE-2 receptor com-
petition assays, such as the MSD assay we used, have been shown 
to correlate well with formal viral neutralization assays, enabling 
use as suitable surrogate functional tests [50]. Recent studies have 
highlighted the potential for SARS-CoV-2 to gain entry to epithe-
lial cells via CD147 receptor [51]. Blocking of this receptor was 
not quantified by our competition assay; whether this influences 
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Figure 5. Surrogate neutralization assay (spike protein [S] and receptor-binding domain [RBD]), with mapping to the final predicted titers at plateau. A, B, Percentage of 
binding plotted against antibody titers. Red lines represent the median antibody titer at which the change in percentage binding is greatest; dotted red lines, 95% confidence 
intervals (CIs). Black lines represent the median posterior distribution of the generalized logistic model, and blue shading, 95% CIs. C, D, Posterior distribution of antibody 
titers at the long-term plateau, as predicted by the gamma-plateau model; shaded gray areas represent thresholds of seronegativity. Abbreviations: MSD, Meso Scale 
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Finally, it remains to be seen to what extent and at what threshold 
long-term detectable antibodies induce sterilizing immunity, limit 
transmission, or simply attenuate disease severity. Human rein-
fection studies and plaque reduction assays >1 year after infection 
are required to clarify this further. SARS-CoV-2–specific T and 
B memory cellular responses must also be characterized to accu-
rately determine durability of immunity. Similarly, mucosal anti-
body responses may play an important role in the overall protective 
immune response, particularly in early infection. The neutralizing 
capability and duration of mucosal IgA responses are currently 
being studied from the same cohort.
In summary, this prospective cohort study has demon-
strated the persistence of SARS-CoV-2 S antibody in >95% of 
individuals up to 200  days after infection. Our lowest-bound 
continuous-decay model predicted that 95% of individuals 
would continue to have detectable S antibody at 465  days, 
while our upper-bound gamma-plateau model predicted that 
the S antibody would plateau at detectable levels indefinitely. 
The long-term presence of functional S (and RBD) antibody 
has important implications for the duration of protective im-
munity after natural infection. It remains to be seen whether 
novel SARS-CoV-2 vaccine candidates will replicate the long 
S-antibody duration induced by natural infection.
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